BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects-Reference-Cited by-同舟云学术

BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects

Published:2020-03-05 Issue:5 Volume:147 Page:1334-1342
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Apostolou Paraskevi¹^ORCID,Fostira Florentia¹,Kouroussis Charalambos²,Kalfakakou Despoina¹,Delimitsou Angeliki¹,Agelaki Sofia³⁴,Androulakis Nikolaos⁵,Christodoulou Christos⁶,Kalbakis Konstantinos⁴,Kalykaki Antonia⁴,Sanidas Elias⁷,Papadimitriou Christos⁸,Vamvakas Lambros⁴,Georgoulias Vassilis⁹,Mavroudis Dimitris³⁴,Yannoukakos Drakoulis¹,Konstantopoulou Irene¹,Saloustros Emmanouil¹⁰

Affiliation:

1. Molecular Diagnostics Laboratory, INRaSTES, National Center for Scientific Research “Demokritos” Athens Greece

2. General Clinic “IASIS”, Chania Crete Greece

3. Laboratory of Translational Oncology School of Medicine, University of Crete Heraklion, Crete Greece

4. Department of Medical Oncology, School of Medicine University Hospital of Heraklion Crete Greece

5. General Hospital of Heraklion "Venizelio‐Pananio" Heraklion Greece

6. Second Department of Medical Oncology Metropolitan Hospital Piraeus Greece

7. Department of Surgery, School of Medicine University of Crete Heraklion Greece

8. Oncology Unit, Second Department of Surgery, Aretaieion Hospital National and Kapodistrian University of Athens Athens Greece

9. Hellenic Oncology Research Group (HORG) Athens Greece

10. Faculty of Medicine, School of Health Sciences University of Thessaly Larissa Greece

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32903

Reference41 articles.

1. Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies

2. Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE

3. Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation

4. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

5. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Concordance between Three Homologous Recombination Deficiency (HRD) Assays in Patients with High-Grade Epithelial Ovarian Cancer;Cancers;2023-11-22

2. MARGINAL: An Automatic Classification of Variants in BRCA1 and BRCA2 Genes Using a Machine Learning Model;Biomolecules;2022-10-24

3. Population Screening in Health Systems;Annual Review of Genomics and Human Genetics;2022-08-31

4. Founder vs. non-founder BRCA1/2 pathogenic alleles: the analysis of Belarusian breast and ovarian cancer patients and review of other studies on ethnically homogenous populations;Familial Cancer;2022-05-21

5. BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients;Current Oncology;2021-11-03